Pharmacy Benefit Manager Fee Disclosure Rule Lawsuit

The Department of Labor issued a final rule requiring providers of pharmacy benefit management services, and affiliated providers of brokerage and consulting services, to disclose information about their compensation to fiduciaries of large, self-insured group health plans governed by ERISA. The rule, “Improving Transparency Into Pharmacy Benefit Manager Fee Disclosure,” appears at 91 FR 69092 and was published on November 2, 2026.

At a glance

• The rule is a final rule from the Labor Department and its Employee Benefits Security Administration, designated document 2026-22306 and published at 91 FR 69092 on November 2, 2026.
• The regulation is effective January 4, 2027.
• It applies to plan years beginning on or after July 1, 2027.
• It touches 29 CFR Part 2550 and carries Regulation Identifier Number 1210-AB37.
• The Department states the rule was issued as directed in section 12 of President Trump’s Executive Order 14273, Lowering Drug Prices by Once Again Putting Americans First.

What the rule requires and who it covers

The rule requires providers of pharmacy benefit management services to disclose information about their compensation to plan fiduciaries. It extends the same disclosure obligation to affiliated providers of brokerage and consulting services.

The Department frames these requirements as serving ERISA’s statutory prohibited transaction exemption for service arrangements under section 408(b)(2), the exemption that lets plans pay service providers when the arrangement is reasonable and the compensation disclosed. In the Department’s account, the disclosures exist so that fiduciaries can assess the reasonableness of contracts or arrangements with these service providers, including the reasonableness of the providers’ compensation.

The rule’s reach is limited by plan type. The Department states it will affect sponsors and other fiduciaries of large, self-insured group health plans and certain service providers to such plans. Its stated rationale is that pharmacy spending is a major driver of overall health care costs for employers and is growing faster than medical and surgical spending.

What is established vs. what is alleged

There is no allegation layer in this record. A final rule published in the Federal Register is an action the agency has taken, not a claim by a private party, and the Federal Register text is the primary record of what the Department did.

What is established in the document: the rule’s title, its document number 2026-22306, its publication date of November 2, 2026, its citation at 91 FR 69092, its candidate pages 69092 to 69196, its effective date of January 4, 2027, and its applicability to plan years beginning on or after July 1, 2027.

What is also established is the Department’s stated reasoning, which is the agency’s own explanation rather than an outside finding. The Department says the disclosures are needed so fiduciaries can assess the reasonableness of service arrangements and compensation. It cites the executive order as its direction and identifies pharmacy spending as a major and fast-growing cost driver for employers.

What the document does not contain is any enforcement record, any list of specific pharmacy benefit managers, or any finding about particular contracts.

Where the rule stands procedurally

The action is a final rule, not a proposed rule. The Federal Register entry lists its action type as “Final rule” and takes the Docket ID EBSA-2026-0001. It is marked as a significant regulatory action and carries priority category “Other Significant” under RIN 1210-AB37.

The docket record shows no open comment period. The regulations.gov entry for the rule reports a comment count of 0, and the docket indicates that regulations.gov is not open for comment. The document lists no corrections and no correction-of relationship to an earlier document.

As of November 2026, there is no federal court consolidation, multidistrict litigation (MDL, a procedure that gathers related federal suits before one judge) or Judicial Panel on Multidistrict Litigation (JPML, the body that decides whether to create an MDL) action associated with this rule in the supplied record.

Key dates

• November 2, 2026: The Labor Department published the final rule at 91 FR 69092, with the regulations.gov docket opened for the rule entry on the same date.
• November 3, 2026: The Federal Register entry shows its page view count last updated, and the regulations.gov check timestamp recorded.
• January 4, 2027: The regulation becomes effective.
• July 1, 2027: The rule first applies to plan years beginning on or after this date.

What this does not establish

The record does not show that any pharmacy benefit manager has changed its contracts, disclosures or fees.

The record does not show any enforcement action, penalty, lawsuit, settlement or verdict connected to the rule.

The record does not name any specific plan sponsor, plan, pharmacy benefit manager or broker, and it does not quantify expected savings, fee reductions or cost effects.

The record does not contain the regulatory text of 29 CFR Part 2550 itself, the preamble discussion of comments received, or a regulatory impact analysis. The supplied document is the Federal Register metadata entry for the rule, so questions about the precise wording of each disclosure requirement, definitions and exemptions fall outside what these documents show.

The record does not establish that the rule will be cited by any particular index or publication, nor any ranking or search visibility outcome.

Frequently asked questions

What does the PBM fee disclosure rule require?

The final rule at 91 FR 69092 requires providers of pharmacy benefit management services, and affiliated providers of brokerage and consulting services, to disclose information about their compensation to fiduciaries of large, self-insured group health plans subject to ERISA. The Department of Labor states the purpose is to let fiduciaries assess the reasonableness of service arrangements and compensation under ERISA section 408(b)(2). The rule was published on November 2, 2026.

When does the pharmacy benefit manager fee disclosure rule take effect?

The Labor Department’s rule is effective January 4, 2027, according to the Federal Register entry for document 2026-22306. The same entry states the rule is applicable to plan years beginning on or after July 1, 2027. Those two dates serve different functions: one governs when the regulation is in force, the other when it first reaches plan years.

Which health plans are covered by the rule?

The Department states the final rule will affect sponsors and other fiduciaries of large, self-insured group health plans, along with certain service providers to those plans. The rule operates through ERISA’s statutory prohibited transaction exemption for service arrangements under section 408(b)(2). The document does not describe coverage of plans outside that description.

Is there any litigation over the PBM fee disclosure rule?

The supplied Federal Register record for document 2026-22306 shows no lawsuit, MDL or JPML proceeding concerning the rule. The document lists no corrections and no court docket. Any later challenge would appear outside this record and would need to be checked against court filings directly.

Sources

1. Federal Register (Labor Department): “Improving Transparency Into Pharmacy Benefit Manager Fee Disclosure” (link, accessed 2026-11-03)
2. Federal Register: “All Documents” (link, accessed 2026-11-03)
3. Federal Register: “Agencies” (link, accessed 2026-11-03)
4. Federal Register: “Documents of type Rule” (link, accessed 2026-11-03)
5. Federal Register: “Documents of type Notice” (link, accessed 2026-11-03)
6. Federal Register: “Documents of type Proposed Rule” (link, accessed 2026-11-03)

Related reading on how federal litigation is organized: how mass tort litigation works and MDL vs. class action.